New Report Suggests Changes to Boost Development of Vital Animal Medications

A recent report from the U.S. Government Accountability Office (GAO) highlights a persistent shortage of approved medications for certain animal species and health conditions, despite existing federal incentives. The GAO’s findings indicate that high development costs and limited market potential have hindered the creation of new drugs, leaving veterinarians and animal owners with fewer treatment options. This scarcity particularly affects less common animals like sheep and fish, as well as serious or rare illnesses in more prevalent pets and livestock.

The report, publicly released on March 3, 2026, examines the effectiveness of the Food and Drug Administration’s (FDA) conditional approval pathway, established in 2004 and later expanded in 2018, which aims to encourage pharmaceutical companies to develop drugs for these underserved areas. Under this pathway, sponsors can gain approval to market a drug while they continue to gather data to prove its effectiveness. However, the GAO found that these incentives have had a limited impact. Between fiscal years 2018 and 2025, the FDA granted conditional approval to 11 new animal drugs, all intended for common species like pets and cattle. As of late January 2026, only two additional drugs had received conditional approval.

A significant hurdle identified by the GAO is the expense and complexity of the studies required to demonstrate a drug’s effectiveness, especially for full FDA approval. While the FDA has provided guidance on alternative study approaches, such as using data from other countries or adjusting sample sizes, the agency has not yet developed a comprehensive benefit-risk assessment framework for evaluating these alternative methods. The GAO recommends that the FDA implement such an assessment and create accompanying industry guidance. This, the report suggests, could encourage sponsors to tackle the development of drugs for unmet animal health needs by providing a clearer framework for demonstrating drug efficacy.

The report also points to the limitations of the conditional approval process itself. Sponsors and other stakeholders have indicated that the flexibilities offered by conditional approval are not sufficient to offset the low profitability of drugs for minor species or uses. A particular point of concern is the statutory five-year limit for sponsors to collect the necessary data for full approval. Many unmet needs, such as treatments for parasites in sheep and goats or bacterial infections in fish, have persisted since the conditional approval pathway was first introduced.

In light of these challenges, the GAO is presenting a matter for congressional consideration: whether to expand the five-year limit on conditional approval. This adjustment, the report notes, could help Congress better balance the competing objectives of increasing the availability of animal drugs, safeguarding animal and human health, and maintaining incentives for companies to invest in less profitable markets. The GAO’s recommendations to the FDA also aim to streamline the approval process for drugs utilizing alternative study designs and provide clearer regulatory pathways for sponsors.

The GAO’s review encompassed statutes, regulations, FDA data, and interviews with FDA officials, drug sponsors, researchers, and other stakeholders. The findings and recommendations are intended to address the ongoing scarcity of approved animal medications and improve the overall health of animal populations.

Article by Mel Anara, based upon information from the U.S. Government Accountability Office

---